Edition:
United States

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

15.24USD
15 Dec 2017
Change (% chg)

$0.34 (+2.28%)
Prev Close
$14.90
Open
$15.08
Day's High
$15.48
Day's Low
$14.96
Volume
927,434
Avg. Vol
257,431
52-wk High
$22.65
52-wk Low
$7.85

Latest Key Developments (Source: Significant Developments)

Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Intra-cellular Therapies Inc ::Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia.Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​.  Full Article

Intra-Cellular Therapies Q3 loss per share $0.53
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.53.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cash, cash equivalents, investment securities totaled $328.1 million at September 30, 2017, versus $384.1 million at December 31, 2016​.Expect to complete patient enrollment in our bipolar studies in 2018​.  Full Article

Intra-Cellular starts enrollment in ITI-214 clinical trial in patients with Parkinson’s disease
Tuesday, 3 Oct 2017 08:00am EDT 

Oct 3 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular therapies announces commencement of enrollment of a clinical trial evaluating ITI-214 in patients with Parkinson’s disease.  Full Article

Intra-Cellular Therapies prices 9.7 mln shares of common stock at $15.50 per share
Wednesday, 27 Sep 2017 10:25pm EDT 

Sept 27 (Reuters) - Intra-Cellular Therapies Inc - :Intra-Cellular therapies prices $150 million public offering of common stock.Announced pricing of previously announced underwritten public offering of 9,677,419 shares of stock at public offering price of $15.50/ share.  Full Article

Intra-Cellular announces proposed public offering of common stock
Tuesday, 26 Sep 2017 04:01pm EDT 

Sept 26 (Reuters) - Intra-Cellular Therapies Inc :Intra-Cellular Therapies announces proposed public offering of common stock.Announced that it has commenced an underwritten public offering of $150 million of shares of its common stock​.Final terms of offering will be disclosed in a final prospectus supplement to be filed with SEC​.  Full Article

Intra-Cellular Therapies announces positive regulatory update on schizophrenia program
Wednesday, 23 Aug 2017 08:00am EDT 

Aug 23 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies announces positive regulatory update on schizophrenia program.Intra-Cellular Therapies Inc- ‍U.S. FDA has informed company that FDA has completed its review of company's responses to requests from FDA​.Intra-Cellular Therapies-‍requests from FDA relate to information regarding some findings in nonclinical toxicology studies of lumateperone in animals.Intra-Cellular Therapies-‍FDA agrees that co presented adequate data to support position metabolic pathway in animal species is distinctive from humans​.Intra-Cellular Therapies-‍moving forward with long-term safety study of lumateperone, intends to submit NDA for treatment of schizophrenia by mid-2018​.  Full Article

Intra-Cellular Therapies reports Q2 loss per share $0.41
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.41.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Intra-Cellular therapies reports Q1 loss per share $0.62
Wednesday, 10 May 2017 07:30am EDT 

May 10 (Reuters) - Intra-cellular Therapies Inc : :Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.62.Q1 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.research and development (research and development) expenses for Q1 of 2017 were $21.5 million, compared to $23.4 million for Q1 of 2016.Intra-Cellular Therapies- cash, cash equivalents and investment securities totaled $367.8 million at march 31, 2017, compared to $384.1 million at December 31, 2016.Qtrly revenues $95,287.  Full Article

Intra-Cellular Therapies provides corporate update on schizophrenia program
Monday, 1 May 2017 07:30am EDT 

May 1 (Reuters) - Intra-cellular Therapies Inc : :Intra-Cellular Therapies provides corporate update on schizophrenia program.Intra-Cellular Therapies - FDA confirmed results of study iti-007-302 do not preclude co from submitting NDA based on efficacy studies conducted to date.Intra-Cellular Therapies - FDA requested information to confirm nonclinical findings are not indicative of safety risk related to long term exposure in humans.FDA has not raised any safety concerns regarding study of lumateperone in short term treatment trials in humans.Intra-Cellular Therapies - if FDA deems responses for nonclinical findings sufficient, to submit NDA for lumateperone for treating schizophrenia by mid-year 2018.  Full Article

Intra-Cellular Therapies Q4 loss per share $0.64
Wednesday, 1 Mar 2017 07:00am EST 

Intra-Cellular Therapies Inc : Intra-Cellular therapies reports fourth quarter and full-year 2016 financial results and provides corporate update . Q4 loss per share $0.64 .Q4 earnings per share view $-0.77 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia